The business intelligence report on ‘global RNA based therapeutics market’, prepared post thorough research of the past and current business scenario, sheds light on the growth patterns of this vertical over 2020-2027. Apart from delineating the drivers and restraints, it promises to enhance the revenue flow of businesses in this domain by uncovering the top opportunities over the forecast period. Moreover, it assesses the industry segments as per their growth potential, including technology landscape, application scope, end-user spectrum, and geographical ambit. Lastly, the research literature offers a comprehensive take on the competitive arena with respect to the leading players, emerging contenders, and new entrants.
As per industry experts and seasoned forecasters, worldwide RNA based therapeutics market, valued USD 0.93 billion in 2019, is anticipated to showcase a healthy growth rate of 28.4% over 2020-2027 and subsequently amass USD 6.87 billion by the end of the assessment period. Mounting cases of various infectious diseases across the globe is the primary growth driver of the industry. In fact, approximately 1.7 million new cases were recorded in 2019, as compared to 2.8 million of the adult population in 1998. In addition, advancements such as RNAi interference technology, antisense technology, and smart technology will further encourage the adoption of RNA based therapeutics in the ensuing years.
Request Sample copy of this Report @ https://www.marketstudyreport.com/request-a-sample/3357824/
Notably, the healthcare sector has aligned its focus towards bringing constancy to RNA molecules in the body with finite bioavailability. For this, RNA therapeutics is under development and when combined with protein/lipid nanoparticles offer better stability. Despite being in clinical research phase, these therapeutics are increasingly researched to find a cure for rare diseases and address unmet medical circumstances. As this field is significantly reliant on research, new technological innovations will continue to expand the overall RNA based therapeutics market size.
Further, strategic collaborations and partnerships by industry players are enhancing the business dynamics. For instance, BioNTech AG, in August 2018, entered a research and development (R&D) collaboration with Pfizer for development of Messenger RNA (mRNA) -based influenza vaccines.
Speaking of the restraints, global RNA based therapeutics market expansion is hindered by high research cost and risk of failure, along with complications in drug delivery.
Regional outlook overview:
North America, Latin America, Europe, and Asia Pacific are the key contributors to global RNA based therapeutics industry remuneration. North America currently accounts for majority industry share, attributable to strong concentration of market vendors, and prompt adoption of new technologies and therapeutics for drug delivery.
Meanwhile, Asia Pacific RNA based therapeutics market is slated to showcase a hefty CAGR over 2020-2027. This can be ascribed to growing prevalence of chronic diseases such as cardiovascular diseases and cancer, along with developing healthcare infrastructure in emerging economies like India and China.
To access a sample copy or view this report in detail along with the table of contents, please click the link below:
Global RNA Based Therapeutics Market Technology Landscape (Revenue, USD Billion, 2017-2027)
- Enabled Technologies (e.g., RNA Interference (RNAi) technologies and RNA antisense technologies)
- Enabling Technologies (such as microarrays, labeling, purification, and others)
Global RNA Based Therapeutics Market Application Scope (Revenue, USD Billion, 2017-2027)
- Kidney Diseases
- Metabolic disorders
- Infectious diseases
Global RNA Based Therapeutics Market End-User Spectrum (Revenue, USD Billion, 2017-2027)
Global RNA Based Therapeutics Market Geographical Bifurcation (Revenue, USD Billion, 2017-2027)
- United States
- United Kingdom
- Rest of Europe
- South Korea
- Rest of APAC
Rest of the World
Global RNA Based Therapeutics Market Competitive Dashboard (Revenue, USD Billion, 2017-2027)
- Sirnaomics, Inc.
- Silence Therapeutics Plc
- Genzyme Corp.
- Cenix BioScience GmbH
- Benitec Biopharma Ltd.
- Tekmira Pharmaceuticals Corp.
- Dicerna Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc.
- Quark Pharmaceuticals, Inc.
U.S. Non-Invasive Prenatal Testing Market - Growth, Demand, Trends, Opportunity, Forecasts (2020 - 2027)
The United States Non-Invasive Prenatal Testing market is anticipated to grow over US$ 2.2 Billion by 2027. The growth in the U.S. Non-Invasive Prenatal Testing (NIPT) market is largely attributed to factors such as the high risk of chromosomal abnormalities with increasing maternal age, increase in incidences of chromosomal aneuploidies among fetus, development of advanced non-invasive prenatal testing products, rising awareness regarding non-invasive prenatal testing, rising focus on reimbursement for NIPT, increasing preference for non-invasive techniques over invasive methods and ACOG guidelines recommend NIPT for all pregnancies regardless of risk.
Market Study Report, LLC. is a hub for market intelligence products and services.
We streamline the purchase of your market research reports and services through a single integrated platform by bringing all the major publishers and their services at one place.
Our customers partner with Market Study Report, LLC. to ease their search and evaluation of market intelligence products and services and in turn focus on their company's core activities.
If you are looking for research reports on global or regional markets, competitive information, emerging markets and trends or just looking to stay on top of the curve then Market Study Report, LLC. is the platform that can help you in achieving any of these objectives.
Market Study Report LLC
Toll Free: 1-866-764-2150
Email: [email protected]